Zerdes, Ioannis http://orcid.org/0000-0002-8304-2462
Simonetti, Michele http://orcid.org/0000-0003-3322-1697
Matikas, Alexios http://orcid.org/0000-0002-4122-9624
Harbers, Luuk http://orcid.org/0000-0003-3910-6497
Acs, Balazs
Boyaci, Ceren http://orcid.org/0000-0001-5598-0243
Zhang, Ning http://orcid.org/0000-0002-6430-4236
Salgkamis, Dimitrios http://orcid.org/0000-0002-3020-0359
Agartz, Susanne
Moreno-Ruiz, Pablo
Bai, Yalai
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Hartman, Johan http://orcid.org/0000-0002-6500-8527
Mezheyeuski, Artur http://orcid.org/0000-0002-4394-2634
Bergh, Jonas http://orcid.org/0000-0001-5526-1847
Crosetto, Nicola http://orcid.org/0000-0002-3019-6978
Foukakis, Theodoros http://orcid.org/0000-0001-8952-9987
Funding for this research was provided by:
Cancerfonden (CAN 2018/846, CAN 2017/1043, CAN 2018/728)
Percy Falks Stiftelse för Forskning Beträffande Prostata- och Bröstcancer
Knut och Alice Wallenbergs Stiftelse
Radiumhemmets Forskningsfonder
Vetenskapsrådet
Stiftelsen för Strategisk Forskning (BD15_0095)
Article History
Received: 18 May 2021
Accepted: 21 October 2021
First Online: 19 November 2021
Competing interests
: I.Z., M.S., A.M., L.H., N.Z., D.S., C.B., B.A., S.A., P.M.-R., Y.B., A.M., and N.C. have no conflicts of interest to disclose. D.L.R. has served as an advisor for Astra Zeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana and Ultivue. Amgen, Cepheid, NavigateBP, NextCure, and Konica Minolta fund research in D.L.R.’s lab; J.H.: speakers honorarium and travel support from Roche, Novartis, AstraZeneca, MSD. Institutional research support from Cepheid; J.B. receives research funding from Merck paid to Karolinska Institutet and from Amgen, Bayer, Pfizer, Roche and Sanofi-Aventis paid to Karolinska University Hospital. No personal payments. Payment from UpToDate for a chapter in breast cancer prediction paid to Asklepios Medicine HB. T.F.: institutional grants from Roche and Pfizer and personal fees from Affibody, Novartis, Pfizer, Roche, Exact Sciences, Veracyte, and UpToDate.